Targeting the chemokine (C-X-C motif) ligand 12 (CXCL12) through the chemokine (C-X-C motif) receptor 4 (CXCR4) inhibitor, AMD3100, in PDAC-bearing mice with anti-PD-L1 therapy significantly reduced tumor volume by 48 h, when compared to controls, with no further decreases in tumor volume over the following 4 days [32]. This evidence concerns the gene CD274 and neoplasm.